Coya Therapeutics Reports 95% Decline in Collaboration Revenue and Increased Net Loss for Q2 2025

Coya Therapeutics, Inc. reported significant financial challenges in its latest 10-Q filing for the quarter ending June 30, 2025. The company generated collaboration revenue of $163,616 for the three months ended June 30, 2025, a stark decline of approximately 95% compared to $3,425,271 in the same period last year. For the six months ending June 30, 2025, total collaboration revenue was $421,500, down from $3,552,109 in the prior year. This decrease is attributed to the immediate recognition of license revenue in the previous year following an amendment to the DRL Development Agreement, which did not recur in the current period.

Operating expenses for Coya increased slightly, totaling $6,578,134 for the three months ended June 30, 2025, compared to $6,661,396 in the same period of 2024. Research and development expenses decreased to $3,663,103 from $4,566,152, while general and administrative expenses rose to $2,908,191 from $2,088,404. The net loss for the quarter was $6,094,977, compared to a loss of $2,891,680 in the prior year, reflecting a significant increase in operational losses. For the six-month period, the net loss was $13,401,734, up from $7,943,593 in 2024.

Coya's balance sheet as of June 30, 2025, showed total assets of $33,452,555, a decrease from $44,347,016 at the end of 2024. Cash and cash equivalents also fell to $29,757,328 from $38,339,762. The company reported an accumulated deficit of $54,138,904, indicating ongoing financial strain. The total liabilities increased to $5,142,262 from $4,769,921, primarily due to higher accrued expenses.

Strategically, Coya has been focused on advancing its product candidates, particularly COYA 302, which is in development for amyotrophic lateral sclerosis (ALS). The company has entered into significant agreements, including the DRL Development Agreement with Dr. Reddy's Laboratories, which grants exclusive rights to commercialize COYA 302 in certain territories. However, the company anticipates needing substantial additional financing to support its operations and product development efforts. Coya's management has indicated that the existing cash reserves are expected to fund operations for at least one year, but additional capital will be necessary to continue its growth strategy and clinical trials.

Looking ahead, Coya Therapeutics remains committed to its research and development initiatives, particularly in enhancing the function of regulatory T cells to address various diseases. The company is preparing for the next stages of clinical trials and aims to secure further funding to support its ambitious pipeline. However, the ability to generate significant revenue from product sales remains uncertain, contingent on successful development and regulatory approval of its product candidates.